{
  "id": "mhgap#referral_d5cc8484",
  "content": "If antiseizure medicine monotherapy is unsuccessful in people with\ngeneralized onset seizures or focal onset seizures, prompt referral should be\nmade to a specialist for consideration of other treatment options.\nStrength of recommendation: Strong\nCertainty of evidence: High\n80\n3. Recommendations\nJustification y All ASMs considered (carbamazepine, lamotrigine,\ny Evidence was extracted from one systematic review oxcarbazepine, topiramate, gabapentin, sodium\nand NMA: Nevitt et al., 2022 (89 trials) (183). valproate, levetiracetam, lacosamide, zonisamide,\nphenytoin, phenobarbital) are effective in\ny For generalized onset seizures there is high-certainty\ncontrolling seizures.\nevidence to suggest that there is no statistically\nsignificant difference in time-to-seizure remission y Lamotrigine, topiramate, sodium valproate,\nby ASM treatment (carbamazepine, lacosamide, levetiracetam, lacosamide, zonisamide and\nlamotrigine, levetiracetam, phenobarbital, phenytoin are considered broad-spectrum\nphenytoin, sodium valproate, topiramate). ASMs effective against multiple seizure types.\nCarbamazepine and oxcarbazepine are ASMs mainly\ny For generalized onset seizures there is high-\nutilized for focal onset seizures. Carbamazepine and\ncertainty evidence to suggest that levetiracetam\noxcarbazepine can be effective against generalized\nand lamotrigine perform significantly better than\ntonic-clonic seizures in people with generalized\ncarbamazepine in terms of adverse events (HR =\nonset epilepsy, although they may exacerbate other",
  "metadata": {
    "source": "WHO mhGAP-IG 2023",
    "url": "https://www.who.int/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "referral",
      "management"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Referral If antiseizure medicine monotherapy is unsuccessful in people with\ngeneralized onset seizures or focal onset seizures, prompt referral should be\nmade to a specialist for consideration of other treatment options.\nStrength of recommendation: Strong\nCertainty of evidence: High\n80\n3. Recommendations\nJustification y All ASMs considered (carbamazepine, lamotrigine,\ny Evidence was extracted from one systematic review oxcarbazepine, topiramate, gabapentin, sodium\nand NMA: Nevitt et al., 2022 (89 trials) (183). valproate, levetiracetam, lacosamide, zonisamide,\nphenytoin, phenobarbital) are effective in\ny For generalized onset seizures there is high-certainty\ncontrolling seizures.\nevidence to suggest that there is no statistically\nsignificant difference in time-to-seizure remission y Lamotrigine, topiramate, sodium valproate,\nby ASM treatment (carbamazepine, lacosamide, levetiracetam, lacosamide, zonisamide and\nlamotrigine, levetiracetam, phenobarbital, phenytoin are considered broad-spectrum\nphenytoin, sodium valproate, topiramate). ASMs effective against multiple seizure types.\nCarbamazepine and oxcarbazepine are ASMs mainly\ny For generalized onset seizures there is high-\nutilized for focal onset seizures. Carbamazepine and\ncertainty evidence to suggest that levetiracetam\noxcarbazepine can be effective against generalized\nand lamotrigine perform significantly better than\ntonic-clonic seizures in people with generalized\ncarbamazepine in terms of adverse events (HR =\nonset epilepsy, although they may exacerbate other If antiseizure medicine monotherapy is unsuccessful in people with\ngeneralized onset seizures or focal onset seizures, prompt chuyển tuyến should be\nmade to a specialist for consideration of other treatment options. stre..."
}